Darzalex Faspro Approval History
FDA Approved: Yes (First approved May 1, 2020)
Brand name: Darzalex Faspro
Generic name: daratumumab and hyaluronidase-fihj
Dosage form: Injection
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Multiple Myeloma
Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase indicated for the treatment of adult patients with multiple myeloma.
Development History and FDA Approval Process for Darzalex Faspro
| Date | Article |
|---|---|
| May 2, 2020 |  FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
